{"commentary":{"count":31,"free_build_floor":8,"listing_floor":3,"by_channel":{"x_thread":21,"podcast":8,"youtube":2},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT05221840\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"PACIFIC-9","nct_id":"NCT05221840","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=pacific-9-nct05221840. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources"},"registry":{"acronym":"PACIFIC-9","arms":[{"description":"Durvalumab on Day 1 of each 28-day cycle + Oleclumab on Days 1 and 15 of cycles 1 and 2, then on Day 1 of each subsequent 28-day cycle for up to 12 months","label":"Arm A: Durvalumab and Oleclumab","type":"EXPERIMENTAL"},{"description":"Durvalumab + Monalizumab on Day 1 of each 28-day cycle for up to 12 months. Placebo infusion will be administered on Day 15 of cycles 1 and 2 only","label":"Arm B: Durvalumab and Monalizumab","type":"EXPERIMENTAL"},{"description":"Durvalumab on Day 1 of each 28-day cycle + Placebo on Days 1 and 15 of cycles 1 and 2, then on Day 1 of each subsequent 28-day cycle for up to 12 months","label":"Arm C: Durvalumab and Placebo","type":"ACTIVE_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2030-07-02","type":"ESTIMATED"},"conditions":["Non-Small Cell Lung Cancer"],"enrollment":{"count":1051,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Durvalumab","type":"DRUG"},{"name":"Oleclumab","type":"DRUG"},{"name":"Monalizumab","type":"DRUG"},{"name":"Placebo","type":"OTHER"}],"last_update":"2026-06-18","lead_sponsor":"AstraZeneca","official_title":"A Phase III, Double-blind, Placebo-controlled, Randomised, Multicentre, International Study of Durvalumab Plus Oleclumab and Durvalumab Plus Monalizumab in Patients With Locally Advanced (Stage III), Unresectable Non-small Cell Lung Cancer (NSCLC) Who Have Not Progressed Following Definitive, Platinum-Based Concurrent Chemoradiation Therapy","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2026-09-30","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Progression Free Surival (PFS)","timeFrame":"Up to 5 years after first patient randomized."}],"references":[{"citation":"Barlesi F, Cho BC, Goldberg SB, Yoh K, Zimmer Gelatti AC, Mann H, Gopinathan A, Bielecka ZF, Newton M, Aggarwal C. PACIFIC-9: Phase III trial of durvalumab + oleclumab or monalizumab in unresectable stage III non-small-cell lung cancer. Future Oncol. 2024;20(29):2137-2147. doi: 10.1080/14796694.2024.2354160. Epub 2024 Jul 18.","pmid":"39023287","type":"DERIVED"}],"start_date":{"date":"2022-02-07","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer","url":"https://clinicaltrials.gov/study/NCT05221840"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/pacific-9-nct05221840"}